Pfizer (PFE) : Buckhead Capital Management scooped up 19,056 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 334,594 shares of Pfizer which is valued at $11,687,368.Pfizer makes up approximately 2.05% of Buckhead Capital Management’s portfolio.
Other Hedge Funds, Including , Leisure Capital Management reduced its stake in PFE by selling 627 shares or 1.06% in the most recent quarter. The Hedge Fund company now holds 58,378 shares of PFE which is valued at $2,039,144. Pfizer makes up approx 2.19% of Leisure Capital Management’s portfolio.New Mexico Educational Retirement Board boosted its stake in PFE in the latest quarter, The investment management firm added 23,400 additional shares and now holds a total of 706,750 shares of Pfizer which is valued at $24,941,208. Pfizer makes up approx 1.09% of New Mexico Educational Retirement Board’s portfolio.Welch Forbes reduced its stake in PFE by selling 294 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 1,043,655 shares of PFE which is valued at $36,830,585. Pfizer makes up approx 1.09% of Welch Forbes’s portfolio.Smith Salley Associates boosted its stake in PFE in the latest quarter, The investment management firm added 10,187 additional shares and now holds a total of 94,976 shares of Pfizer which is valued at $3,503,665. Pfizer makes up approx 0.79% of Smith Salley Associates’s portfolio.Neville Rodie Shaw Inc reduced its stake in PFE by selling 1,210 shares or 0.58% in the most recent quarter. The Hedge Fund company now holds 207,726 shares of PFE which is valued at $7,542,531. Pfizer makes up approx 0.88% of Neville Rodie Shaw Inc’s portfolio.
Pfizer opened for trading at $34.75 and hit $35.15 on the upside on Wednesday, eventually ending the session at $35.14, with a gain of 1.01% or 0.35 points. The heightened volatility saw the trading volume jump to 1,70,40,893 shares. Company has a market cap of $213,147 M.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.